Immunological signatures and parameters predicting therapeutic responses to anti-TNF therapy

Abstract

The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.

Claims

1. A method, comprising: a) obtaining a culture of immune cells from a biological sample taken from a patient having a chronic inflammatory disease, wherein the biological sample is collected prior to an anti-TNF therapy; b) stimulating the culture of immune cells with an agent that stimulates the innate or adaptive immune system; and c) measuring the expression level in the culture of immune cells of at least one cytokine and/or matrix metalloproteinase (MMP).

2. The method according to claim 1, wherein said chronic inflammatory disease is rheumatoid arthritis or a disease of the spondyloarthritis (SpA) group.

3. The method of claim 2, wherein the SpA group disease is selected from psoriatic arthritis, reactive arthritis, arthritis related to inflammatory bowel disease, a subgroup of juvenile chronic arthritis and ankylosing spondylitis.

4. The method according to claim 1, wherein said agent that stimulates the innate or adaptive immune system is chosen from a heat-killed live, attenuated or killed microbe and a Toll-like receptor agonist.

5. The method of claim 1, wherein the culture of immune cells is stimulated with Helicobacter pylori or Influenza A virus.

6. The method of claim 1, wherein the cytokine is selected from the group consisting of: IFN-gamma, IL-1 beta, IL-12p70, IL-1ra, IL-17, IL-2, IL-4, MCP1, MIP-1 alpha, MIP-1 beta, TNF-alpha and TNF-beta and the MMP is MMP-9.

7. The method of claim 1, wherein the expression level is measured by measuring mRNA expression level.

8. The method of claim 1, wherein the expression level is measured by measuring protein expression level.

9. The method of claim 6, wherein the expression level of the at least one of IL-1ra, MIP-1beta, and TNF-alpha is increased.

10. The method of claim 6, wherein the expression level of IL-1ra is increased, the expression level of MIP-1beta is increased, and the expression level of TNF-alpha is increased.

11. The method of claim 1, wherein the biological sample taken from a patient is whole blood.

12. A method, comprising: a) obtaining a first culture of immune cells from a biological sample taken from a patient having a chronic inflammatory disease, wherein the biological sample is collected prior to an anti-TNF therapy; b) stimulating the first culture of immune cells with a first agent that stimulates the innate or adaptive immune system; c) measuring the expression level in the first culture of immune cells of at least one cytokine and/or matrix metalloproteinase (MMP) in the first culture of immune cells; d) obtaining a second culture of immune cells from the patient; e) stimulating the second culture of immune cells with a second agent that stimulates the innate or adaptive immune system; and f) measuring the expression level in the second culture of immune cells of at least one cytokine and/or matrix metalloproteinase (MMP) in the second culture.

13. The method according to claim 12, wherein said chronic inflammatory disease is rheumatoid arthritis or a disease of the spondyloarthritis (SpA) group.

14. The method of claim 13, wherein the SpA group disease is selected from psoriatic arthritis, reactive arthritis, arthritis related to inflammatory bowel disease, a subgroup of juvenile chronic arthritis and ankylosing spondylitis.

15. The method of claim 14, wherein the SpA group disease is ankylosing spondylitis.

16. The method of claim 12, wherein the expression level of IL-1ra, MIP-1beta, and TNF-alpha is measured in the first culture of immune cells and the expression level of IL-1ra, MIP-1beta, and TNF-alpha is measured in the second culture of immune cells.

17. The method of claim 12, wherein the expression level is measured by measuring mRNA expression level.

18. The method of claim 12, wherein the expression level is measured by measuring protein expression level.

19. The method of claim 12, wherein the expression level of the at least one of IL-1ra, MIP-1beta, and TNF-alpha is increased in the first culture of immune cells and in the second culture of immune cells.

20. The method of claim 12, wherein the expression level of IL-1ra is increased, the expression level of MIP-1beta is increased, and the expression level of TNF-alpha is increased in the first culture of immune cells; and wherein the expression level of IL-1ra is increased, the expression level of MIP-1beta is increased, and the expression level of TNF-alpha is increased in the second culture of immune cells.

21. A method, comprising: a) obtaining a culture of immune cells from a biological sample taken from a patient having a chronic inflammatory disease, wherein the biological sample is collected prior to an anti-TNF therapy; b) stimulating the culture of immune cells with an agent that stimulates the innate or adaptive immune system; and c) measuring the expression level in the culture of immune cells of IL-1ra, MIP-1beta, and TNF-alpha; wherein the expression level of IL-1ra is increased, the expression level of MIP-1beta is increased, and the expression level of TNF-alpha is increased.

22. A method, comprising: a) obtaining a first culture of immune cells from a biological sample taken from a patient having a chronic inflammatory disease, wherein the biological sample is collected prior to an anti-TNF therapy; b) stimulating the first culture of immune cells with a first agent that stimulates the innate or adaptive immune system; c) measuring the expression level in the first culture of immune cells of IL-1ra, MIP-1beta, and TNF-alpha; d) obtaining a second culture of immune cells from the patient; e) stimulating the second culture of immune cells with a second agent that stimulates the innate or adaptive immune system; and f) measuring the expression level in the second culture of immune cells of IL-1ra, MIP-1beta, and TNF-alpha; wherein the expression level of IL-1ra is increased, the expression level of MIP-1beta is increased, and the expression level of TNF-alpha is increased in the first culture of immune cells; and wherein the expression level of IL-1ra is increased, the expression level of MIP-1beta is increased, and the expression level of TNF-alpha is increased in the second culture of immune cells.

Description

(1) In addition to the preceding features, the invention further comprises other features that will emerge from the description that follows, which refers to examples illustrating the methods and uses according to the present invention, as well as to the appended drawings in which:

(2) FIG. 1: Design of the pilot study. Twelve patients with a definitive diagnosis of SpA and indications for treatment with TNF-blockers were enrolled. Blood samples were collected prior to starting treatment with TNF blockers, and 3 months after the beginning of anti-TNF therapy. Clinical and biological efficacy was monitored at week 12 according to the current standard of care.

(3) FIG. 2: An Immunologic signature of anti-TNF therapy. The levels of 31 secreted molecules (analytes) in response to 18 immune stimuli included in each of the TruCulture assays were compared in samples from patients obtained before (visit 1, black rectangles) and 3 months after initiation of anti-TNF therapy (visit 2, grey rectangles). The stimuli TNF and TNF+IL-1β, as well as TNF levels in the supernatant were excluded from the analysis because of possible interference with residual TNF blockers in the circulation of SpA patients. Shown is a heat map representation generated by agglomerative hierarchical clustering using Qlucore Omics explorer software (version 3.0). Of the 558 combinations tested, 30 reached a significance level of at least 0.001 (Wilcoxon matched-pairs test).

(4) FIG. 3: Therapeutic responses to anti-TNF therapy. The “Ankylosing Spondylitis Disease Activity Score” (ASDAS) was calculated for each patient (Machado et al., 2011; Machado et al., 2015; van der Heijde et al., 2009) before treatment and 3 months after initiation of anti-TNF therapy. Shown is the “Improvement Score” (ASDAS.sub.before treatment−ASDAS.sub.after treatment) for each patient included in this study. Patients were grouped into non-responders (white bars), partial responders (grey bars), and responders (black bars) based on the improvement score.

(5) FIG. 4: Immunologic parameters before anti-TNF therapy that correlate with subsequent therapeutic responses to TNF-blockers. Patients were grouped into non-responders (white squares), partial responders (grey squares), and responders (black squares) based on the improvement score as described in FIG. 3. Samples collected before initiation of anti-TNF therapy (Visit 1) were stimulated with 20 different immune stimuli, and 32 secreted molecules were analyzed for each assay. A multi-group comparison of the 640 parameters was performed to identify combinations of analytes and stimuli (rows) that can discriminate the three patient groups before initiation of anti-TNF therapy. Hierarchical clustering shows that patients responding to anti-TNF therapy (high improvement score) express higher levels (indicated by the light shading in the heat map) of IL-1ra, MIP-1beta and other secreted molecules in response to specific stimuli, compare to non-responders or partial responders.

(6) FIG. 5: Parameters correlating with therapeutic responses to TNF blockers before anti-TNF therapy. Shown are the levels of IL-1ra (left panels), MIP-1beta (middle panels) and TNF (right panels) in TruCulture supernatants following stimulation with H. pylori (upper panels), influenza virus (middle panels) and medium alone (“Null”; lower panels) of blood cultures from SpA patients before anti-TNF therapy (visit 1, as described for FIG. 4). Patients were grouped according to therapeutic response to TNF blockers; NR, non-responders; PR, partial responders; and R, responders. The dotted line indicates the concentration of the indicated cytokine or chemokine following stimulation that allows identification of patients responding to anti-TNF therapy.

EXAMPLE: IMMUNOLOGIC PARAMETERS PREDICTING THERAPEUTIC RESPONSES TO TNF BLOCKERS IN SpA PATIENTS

(7) Developing biomarkers that will help patients and physicians to choose the most effective therapy is an unmet medical need that needs to be urgently addressed. To address this issue, the inventors have hypothesized that the analysis of the immune functions of patients will allow them to define objective criteria (biomarkers) to predict therapeutic responses to anti-TNF therapy. This hypothesis was tested in a pilot study involving 12 SpA patients with axial involvement and indications for anti-TNF treatment, using the “TruCulture” system disclosed in Duffy et al. (2014) for analyzing the immune response of the patients.

(8) The study was designed to address two questions; (i) what is the impact of anti-TNF therapy on immune responses to microbial challenges and stimuli targeting specific pathways in SpA patients? and (ii) is it possible to identify immunological correlates of responsiveness to TNF blockers before the initiation of anti-TNF therapy? The design of the study is shown in FIG. 1.

(9) 1. Patients and Methods

(10) Patients

(11) Peripheral blood samples were obtained from 12 patients with spondyloarthritis in the Department of Rheumatology (Cochin Hospital, Paris, France). All the patients met either the modified New York criteria for ankylosing spondylitis or the Amor criteria for spondyloarthritis (Amor et al., 1990; van der Linden et al., 1984). Age, sex, disease duration, HLA-B27 positivity and the type of clinical presentation (axial involvement, peripheral arthritis, enthesis and non rheumatologic symptoms) were recorded. Current treatment was also noted at the time of sampling. The patients were all adults and had never received biologic anti-rheumatic agents. The first sample (visit 1) was obtained before anti-TNF therapy and the second sample three months after initiation of anti-TNF therapy. Sampling for visit 2 was performed one week after the last injection of TNF blockers (Etanercept for 11 patients and Adalimumab for 1 patient).

(12) The study was approved by the Ethical Review Committee “Comité de Protection des Personnes Ile de France III” and written informed consent was given by all patients prior to inclusion in the study.

(13) Whole Blood Assays to Assess Immune Responses in SpA Patients

(14) Whole blood assays was performed using the same standardized and validated procedure as previously disclosed in Duffy et al., 2014. Briefly, TruCulture tubes were prepared in batch with the indicated stimulus, resuspended in a volume of 2 ml buffered media and maintained at −20° C. until time of use. Blood was obtained from the antecubital vein using vacutainers coated with Sodium-Heparin. Within twenty minutes of collection, 1 ml of whole blood was distributed into each of the pre-warmed TruCulture tubes, inserted into a dry block incubator and maintained at 37° C., room air for 22 hr. At the end of the incubation period, tubes were opened and a valve was inserted in order to separate the sedimented cells from the supernatant and to stop the stimulation reaction. Liquid supernatants were aliquoted and immediately frozen at −80° C. until the time of use. 32 secreted molecules were analyzed in a CLIA-certified laboratory using Human CytokineMAP® A and B (Myriad RBM).

(15) Statistical Analysis

(16) A two-tailed Wilcoxon matched-pairs test was used to analyze the effects of anti-TNF therapy on the production of cytokines and chemokines. Agglomerative hierarchical clustering, paired t-test (FIG. 2) and ANOVA testing (FIG. 4) were performed with Qlucore Omics Explorer, version 3.0 (Qlucore, Lund, Sweden).

(17) 2. Results

(18) TNF Blockers Affect Immune Responses in SpA Patients

(19) Freshly drawn whole blood was stimulated in TruCulture tubes with 20 different stimuli for 22 hours as described above. Supernatants were frozen at −80° C. and 32 secreted molecules were analyzed in a CLIA-certified laboratory. First, the levels of secreted molecules in the supernatants of TruCulture assays were compared before and 3 months after initiation of anti-TNF therapy. A highly significant reduction of the secretion of IL-1ra in response to microbial stimuli such as gram-positive bacteria (S. aureus), gram-negative bacteria (H. pylori), yeast (C. albicans) and viruses (influenza) was noted in blood samples collected 3 months after start of anti-TNF therapy. Production of IL-1ra was also strongly reduced following stimulation with agonists targeting specific toll-like receptors (TLRs), such as LPS, and gardiquimod. Reduced production of other pro-inflammatory cytokines and chemokines, such as IL-6 and MIP-1β, were also observed in blood samples from patients after treatment with TNF blockers.

(20) To obtain an overview of the effects of anti-TNF therapy on immune responses in SpA patients, a comprehensive analysis was performed by comparing the levels of 31 secreted molecules in response to 18 immune stimuli included in each of the TruCulture assays. The stimuli TNF and TNF+IL-1, as well as TNF levels in the supernatant were excluded from the analysis because of possible interference with residual TNF blockers in the circulation of SpA patients. FIG. 2 shows a heat map representation of a paired analysis of the levels of 31 secreted molecules induced by 18 stimuli. Of the 558 combinations tested, 30 reached a significance level of at least 0.001 (Wilcoxon matched pairs test). This analysis revealed that in addition to several pro-inflammatory cytokines and chemokines, the levels of the matrix metalloproteinase MMP-9 were significantly reduced in response to several stimuli after anti-TNF therapy. Also, the levels of the chemokine eotaxin-1 (CCL11) and of brain-derived neurotrophic factor (BDNF) were increased in blood samples from patients obtained after treatment with TNF blockers.

(21) Together, these data show that anti-TNF therapy strongly affects the immune responses of patients to various pathogens as well as to stimuli targeting specific signaling pathways. It is also important to note that the effects of anti-TNF therapy on immune responses can be measured when immune cells are challenged, but not at steady state (“null stimulus” cultures).

(22) Immunologic Parameters Predicting Therapeutic Responses to TNF Blockers in SpA Patients

(23) Given the robust effects of anti-TNF therapy on immune responses to microbial challenges and agonists triggering various signaling pathways in SpA patients, the inventors next asked whether they could establish a correlation between the responses of immune cells to specific stimuli and the therapeutic response to TNF-blockers. For this, the “Ankylosing Spondylitis Disease Activity Score” (ASDAS) (Machado et al., 2011; Machado et al., 2015; van der Heijde et al., 2009) was calculated before treatment and 3 months after initiation of anti-TNF therapy and the “Improvement Score” (ASDAS.sub.before treatment−ASDAS.sub.after treatment) was determined. Patients were grouped into three groups according to the improvement score. Among the 12 patients recruited to the pilot study, 3 (25%) showed a major improvement (responders), 4 (33%) had a clinically important improvement (partial responders), and 5 (42%) did not respond to anti-TNF therapy (FIG. 3). Then a multi-group comparison (ANOVA) was performed to identify immune parameters that correlate with therapeutic responses to TNF blockers. The data show that SpA patients who secreted the highest levels of inflammatory molecules in response to immune stimuli before initiation of anti-TNF therapy have the best therapeutic responses (highest improvement score) (FIG. 4). Among the 20 stimuli and 32 cytokines and chemokines tested in this analysis, the levels of IL-1ra, MIP-1 and TNF following stimulation with H. Pylori and influenza virus were substantially higher in SpA patients with a major improvement after anti-TNF therapy than patients with a partial therapeutic response or non-responding patients (FIG. 5). In fact, cut-off values for the concentrations of each of these molecules in response to the two stimuli that can discriminate patients responding to anti-TNF therapy from those not-responding or only with a partial response have been identified. In contrast, the low levels of these molecules in TruCulture assays not containing stimuli did not allow prediction of therapeutic responses (FIG. 5, lower panels).

(24) These results demonstrate that the analysis of immune responses to specific stimuli in patients before therapy is an efficient strategy to develop biomarkers to predict therapeutic efficacy of TNF-blockers.

CONCLUSIONS

(25) 1) Anti-TNF therapy alters immune responses to pathogens and stimuli targeting specific pathways in SpA patients. 2) These changes can be detected in stimulated immune cells, but not at baseline. 3) The inventors have identified combinations of stimuli and cytokines and chemokines that correlate with therapeutic response to TNF-blockers. 4) Analyzing immune responses to specific stimuli in patients before therapy is a novel and efficient strategy to develop biomarkers predicting therapeutic responses to TNF-blockers.

REFERENCES

(26) Amor, B., Dougados, M., and Mijiyawa, M. (1990). Criteria of the classification of spondylarthropathies. Revue du rhumatisme et des maladies osteo-articulaires 57, 85-89. Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J. M., Landewe, R., Wordsworth, P., et al. (2013a). Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382, 1705-1713. Baeten, D., Breban, M., Lories, R., Schett, G., and Sieper, J. (2013b). Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum 65, 12-20. Braun, J., Listing, J., and Sieper, J. (2005). Reply. Arthritis & Rheumatism 52, 4049-4050. Dougados, M., and Baeten, D. (2011). Spondyloarthritis. Lancet 377, 2127-2137. Duffy, D., Rouilly, V., Libri, V., Hasan, M., Beitz, B., David, M., Urrutia, A., Bisiaux, A., Labrie, S. T., Dubois, A., et al. (2014). Functional Analysis via Standardized Whole-Blood Stimulation Systems Defines the Boundaries of a Healthy Immune Response to Complex Stimuli. Immunity 40, 436-450. International Genetics of Ankylosing Spondylitis, C., Cortes, A., Hadler, J., Pointon, J. P., Robinson, P. C., Karaderi, T., Leo, P., Cremin, K., Pryce, K., Harris, J., et al. (2013). Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nature genetics 45, 730-738. Jenkinson, T. R., Mallorie, P. A., Whitelock, H. C., Kennedy, L. G., Garrett, S. L., and Calin, A. (1994). Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21, 1694-1698. Machado, P., Landewe, R., Lie, E., Kvien, T. K., Braun, J., Baker, D., van der Heijde, D., and Assessment of SpondyloArthritis international, S. (2011). Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70, 47-53. Machado, P., Navarro-Compan, V., Landewe, R., van Gaalen, F. A., Roux, C., and van der Heijde, D. (2015). Calculating the ankylosing spondylitis disease activity score if the conventional c-reactive protein level is below the limit of detection or if high-sensitivity c-reactive protein is used: an analysis in the DESIR cohort. Arthritis & rheumatology 67, 408-413. Robinson, P. C., and Brown, M. A. (2014). Genetics of ankylosing spondylitis. Molecular immunology 57, 2-11. Rudwaleit, M., Jurik, A. G., Hermann, K. G., Landewe, R., van der Heijde, D., Baraliakos, X., Marzo-Ortega, H., Ostergaard, M., Braun, J., and Sieper, J. (2009). Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68, 1520-1527. Rudwaleit, M., Metter, A., Listing, J., Sieper, J., and Braun, J. (2006). Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54, 569-578. Smith, J. A., and Colbert, R. A. (2014). Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis & rheumatology 66, 231-241. Thomas, S., Rouilly, V., Patin, E., Alanio, C., Dubois, A., Delval, C., Marquier, L. G., Fauchoux, N., Sayegrih, S., Vray, M., et al. (2015). The Milieu Interieur study—an integrative approach for study of human immunological variance. Clinical immunology 157, 277-293. van der Heijde, D., Lie, E., Kvien, T. K., Sieper, J., Van den Bosch, F., Listing, J., Braun, J., and Landewe, R. (2009). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68, 1811-1818. van der Linden, S., Valkenburg, H. A., and Cats, A. (1984). Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27, 361-368.